Acinetobacter baumannii is a critical-priority, multidrug-resistant pathogen that poses a severe threat in hospitals worldwide. A key structure of these bacteria is the protective layer of complex ...

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

A new study from Emory University addresses the growing global crisis of antibiotic-resistant infections. Many of these drug-resistant bacteria are spread through hospitals, and there are few ...

A new drug that could help combat one of the world's most dangerous drug-resistant bacteria is now entering its final stage of human trials. This potential breakthrough could help in the global fight ...

A study published April 17 by BMC Infectious Diseases found increased incidents of Acinetobacter baumannii and carbapenem-resistant A. baumannii infections between 2018 to 2022. A. baumannii is a ...

This summary highlights only some of the key features and terms of the actual license. It is not a license and has no legal value. Carefully review the actual license before using these materials.

The type VI secretion system (T6SS) is a sophisticated, contact-dependent nanomachine involved in interbacterial competition. To function effectively, the T6SS must penetrate the membranes of both ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...